1. Home
  2. RARE

RARE

Ultragenyx Pharmaceutical Inc.

Logo Ultragenyx Pharmaceutical Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 3:31pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Founded: 2010 Country:
United States
United States
Employees: N/A City: NOVATO
Market Cap: 3.9B IPO Year: 2014
Target Price: $91.25 AVG Volume (30 days): 734.1K
Analyst Decision: Buy Number of Analysts: 12
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -8.25 EPS Growth: N/A
52 Week Low/High: $31.52 - $54.98 Next Earning Date: 05-02-2024
Revenue: $434,249,000 Revenue Growth: 19.52%
Revenue Growth (this year): 20.53% Revenue Growth (next year): 25.86%

Share on Social Networks: